Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,518,842
  • Shares Outstanding, K 77,457
  • Annual Sales, $ 914,960 K
  • Annual Income, $ 377,660 K
  • 60-Month Beta 2.05
  • Price/Sales 4.68
  • Price/Cash Flow 10.32
  • Price/Book 1.90
Trade CRSP with:

Options Overview Details

View History
  • Implied Volatility 73.79% ( -4.16%)
  • Historical Volatility 84.53%
  • IV Percentile 63%
  • IV Rank 44.44%
  • IV High 103.07% on 05/11/22
  • IV Low 50.36% on 09/17/21
  • Put/Call Vol Ratio 0.37
  • Today's Volume 1,479
  • Volume Avg (30-Day) 1,555
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 75,247
  • Open Int (30-Day) 74,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -2.23
  • Number of Estimates 11
  • High Estimate -1.92
  • Low Estimate -2.48
  • Prior Year 9.44
  • Growth Rate Est. (year over year) -123.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.51 +37.24%
on 05/12/22
58.56 -0.38%
on 05/27/22
+6.38 (+12.28%)
since 04/27/22
3-Month
42.51 +37.24%
on 05/12/22
70.94 -17.76%
on 03/18/22
-1.39 (-2.33%)
since 02/25/22
52-Week
42.51 +37.24%
on 05/12/22
169.76 -65.63%
on 06/30/21
-60.06 (-50.73%)
since 05/27/21

Most Recent Stories

More News
Have $2,000? 2 Market Crash-Ready Stocks to Buy

These stocks have great long-term prospects.

VRTX : 273.73 (+1.51%)
CRSP : 58.34 (+5.63%)
PFE : 53.91 (-0.15%)
BHVN : 143.37 (+0.13%)
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why

Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.

VRTX : 273.73 (+1.51%)
MRNA : 147.66 (+8.73%)
ABBV : 150.00 (-0.38%)
CRSP : 58.34 (+5.63%)
Why Orphan Drug Designation Offers Several Benefits

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here...

CRDL : 1.2700 (+0.79%)
CRDL.TO : 1.62 (-0.61%)
ABBV : 150.00 (-0.38%)
CRSP : 58.34 (+5.63%)
CYTK : 41.87 (+7.39%)
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...

CRSP : 58.34 (+5.63%)
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

ALKS : 30.54 (+4.02%)
VRTX : 273.73 (+1.51%)
CRSP : 58.34 (+5.63%)
SESN : 0.5300 (+1.47%)
2 Stocks With 75% to 183% Upside, According to Wall Street

These two companies have been southbound lately.

MRNA : 147.66 (+8.73%)
CRSP : 58.34 (+5.63%)
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...

CRSP : 58.34 (+5.63%)
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates

CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.

ALKS : 30.54 (+4.02%)
VRTX : 273.73 (+1.51%)
ANGN : 1.5000 (+13.64%)
CRSP : 58.34 (+5.63%)
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

CRSP : 58.34 (+5.63%)
RAPT : 14.58 (+8.64%)
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- ...

CRSP : 58.34 (+5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 63.84
2nd Resistance Point 61.20
1st Resistance Point 59.77
Last Price 58.34
1st Support Level 55.70
2nd Support Level 53.06
3rd Support Level 51.63

See More

52-Week High 169.76
Fibonacci 61.8% 121.15
Fibonacci 50% 106.14
Fibonacci 38.2% 91.12
Last Price 58.34
52-Week Low 42.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar